Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Ingrid Delaet Sells 1,091 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total value of $147,285.00. Following the transaction, the insider now owns 2,507 shares of the company's stock, valued at $338,445. This represents a 30.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Neurocrine Biosciences Trading Down 0.4 %

NBIX stock traded down $0.49 during midday trading on Thursday, hitting $134.96. The stock had a trading volume of 983,037 shares, compared to its average volume of 878,463. The business has a fifty day moving average price of $123.14 and a two-hundred day moving average price of $130.61. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98. The firm has a market cap of $13.66 billion, a P/E ratio of 36.18 and a beta of 0.34.

Analysts Set New Price Targets

A number of equities analysts recently commented on NBIX shares. BMO Capital Markets lowered their price target on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating on the stock in a research report on Thursday, October 17th. Piper Sandler upgraded shares of Neurocrine Biosciences from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $131.00 to $159.00 in a research report on Thursday, August 29th. HC Wainwright reissued a "buy" rating and set a $190.00 price target on shares of Neurocrine Biosciences in a report on Monday. Raymond James reiterated an "outperform" rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $155.00 price target on shares of Neurocrine Biosciences in a report on Monday, September 16th. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $166.00.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of NBIX. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Neurocrine Biosciences by 0.8% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company's stock worth $1,574,000 after buying an additional 90 shares during the period. Fifth Third Bancorp raised its stake in shares of Neurocrine Biosciences by 14.7% in the second quarter. Fifth Third Bancorp now owns 716 shares of the company's stock worth $99,000 after purchasing an additional 92 shares during the last quarter. Total Clarity Wealth Management Inc. lifted its holdings in shares of Neurocrine Biosciences by 4.3% in the second quarter. Total Clarity Wealth Management Inc. now owns 2,433 shares of the company's stock valued at $335,000 after purchasing an additional 100 shares in the last quarter. Commerce Bank lifted its stake in Neurocrine Biosciences by 2.6% during the 3rd quarter. Commerce Bank now owns 4,199 shares of the company's stock valued at $484,000 after acquiring an additional 108 shares in the last quarter. Finally, Caprock Group LLC boosted its holdings in Neurocrine Biosciences by 7.0% during the 2nd quarter. Caprock Group LLC now owns 1,669 shares of the company's stock worth $230,000 after acquiring an additional 109 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.